Amarin Plc (AMRN) Holder Consonance Capital Management LP Boosted Its Holding by $58.27 Million; As Johnson & Johnson (JNJ) Stock Declined, Doheny Asset Management Has Decreased Its Stake

Johnson & Johnson (NYSE:JNJ) Logo

Doheny Asset Management decreased its stake in Johnson & Johnson (JNJ) by 17.75% based on its latest 2018Q4 regulatory filing with the SEC. Doheny Asset Management sold 6,600 shares as the company’s stock declined 5.44% while stock markets rallied. The institutional investor held 30,583 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $3.95M, down from 37,183 at the end of the previous reported quarter. Doheny Asset Management who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $366.40B market cap company. The stock decreased 0.30% or $0.42 during the last trading session, reaching $137.6. About 11.92 million shares traded or 36.66% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 8.80% since March 17, 2018 and is uptrending. It has outperformed by 4.43% the S&P500. Some Historical JNJ News: 21/03/2018 – Bloomberg Big Decisions: Johnson & Johnson CEO Alex Gorsky (Video); 27/03/2018 – FDA: Johnson & Johnson Consumer, Inc.- COACH® Self-Adhering Sports Wrap (size: 3in); 16/03/2018 – JOHNSON & JOHNSON: BINDING OFFER FROM PLATINUM EQUITY TO BUY; 29/03/2018 – lnvokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) Drug Analysis 2018 – ResearchAndMarkets.com; 18/04/2018 – KENTUCKY SUES JOHNSON & JOHNSON, ACCUSES COMPANY OF DEVISING DECEPTIVE OPIOID MARKETING SCHEME; 17/04/2018 – Johnson & Johnson 1Q Net $4.37B; 17/04/2018 – J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout $JNJ; 22/03/2018 – EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challenge; 18/04/2018 – Johnson & Johnson/biosimilars: immune to reason; 17/04/2018 – J&J 1Q ADJ EPS $2.06, EST. $2.00

Consonance Capital Management Lp increased its stake in Amarin Corp Plc (AMRN) by 90.21% based on its latest 2018Q4 regulatory filing with the SEC. Consonance Capital Management Lp bought 4.48M shares as the company’s stock rose 24.22% with the market. The hedge fund held 9.45 million shares of the major pharmaceuticals company at the end of 2018Q4, valued at $128.63 million, up from 4.97M at the end of the previous reported quarter. Consonance Capital Management Lp who had been investing in Amarin Corp Plc for a number of months, seems to be bullish on the $6.70 billion market cap company. The stock decreased 1.17% or $0.24 during the last trading session, reaching $20.33. About 6.02M shares traded. Amarin Corporation plc (NASDAQ:AMRN) has risen 537.69% since March 17, 2018 and is uptrending. It has outperformed by 533.32% the S&P500. Some Historical AMRN News: 12/03/2018 – Vascepa® (lcosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and lnflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP); 02/05/2018 – Amarin 1Q Rev $43.9M; 21/03/2018 – AMARIN : LEBANON APPROVES VASCEPA FOR SALE; 02/05/2018 – Amarin 1Q Loss/Shr $0.08; 24/05/2018 – AMARIN REPORTS PATENT LITIGATION SETTLEMENT PACT WITH TEVA; 04/04/2018 – Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events; 23/04/2018 – Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer; 02/05/2018 – Amarin 1Q Loss/Shr 8c; 04/04/2018 – Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives; 12/03/2018 – VASCEPA® (ICOSAPENT ETHYL) SHOWED REDUCTIONS IN POTENTIALLY ATHEROGENIC LIPIDS AND INFLAMMATORY MARKERS IN PATIENTS WITH PERSISTENT HIGH TRIGLYCERIDES AND ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN

Since September 24, 2018, it had 0 buys, and 23 selling transactions for $74.82 million activity. Zakrzewski Joseph S also sold $6.88M worth of Amarin Corporation plc (NASDAQ:AMRN) shares. 200,000 shares were sold by Kalb Michael Wayne, worth $3.05 million on Wednesday, January 9. 879,241 Amarin Corporation plc (NASDAQ:AMRN) shares with value of $9.76M were sold by Ketchum Steven B. On Thursday, January 10 Ekman Lars sold $2.43 million worth of Amarin Corporation plc (NASDAQ:AMRN) or 140,416 shares. $2.26M worth of Amarin Corporation plc (NASDAQ:AMRN) was sold by STACK DAVID M.

More notable recent Amarin Corporation plc (NASDAQ:AMRN) news were published by: Businesswire.com which released: “Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders – Business Wire” on March 15, 2019, also Nasdaq.com with their article: “Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-ITâ„¢ Trial to Be Presented Regarding Reduction in Total Ischemic Events – Nasdaq” published on March 04, 2019, Globenewswire.com published: “AMARIN CORPORATION PLC INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Amarin Corporation plc – GlobeNewswire” on February 27, 2019. More interesting news about Amarin Corporation plc (NASDAQ:AMRN) were released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” published on March 08, 2019 as well as Seekingalpha.com‘s news article titled: “Amarin: Vascepa’s Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT – Seeking Alpha” with publication date: February 20, 2019.

Investors sentiment increased to 1.65 in 2018 Q4. Its up 0.02, from 1.63 in 2018Q3. It increased, as 18 investors sold AMRN shares while 47 reduced holdings. 66 funds opened positions while 41 raised stakes. 139.69 million shares or 10.77% more from 126.12 million shares in 2018Q3 were reported. M&T Fincl Bank owns 14,504 shares. Federated Investors Inc Pa invested in 1.03 million shares or 0.04% of the stock. Us Bankshares De, Minnesota-based fund reported 4,105 shares. Pura Vida Ltd Liability Corporation has 3.3% invested in Amarin Corporation plc (NASDAQ:AMRN) for 389,480 shares. Sg Americas Securities Ltd Com holds 0.01% of its portfolio in Amarin Corporation plc (NASDAQ:AMRN) for 51,413 shares. Hendershot Investments has invested 0.05% of its portfolio in Amarin Corporation plc (NASDAQ:AMRN). California-based Sterling Strategies Ltd Limited Liability Company has invested 0% in Amarin Corporation plc (NASDAQ:AMRN). Raymond James Financial Services Inc accumulated 240,701 shares. Fred Alger Mgmt owns 70,000 shares. Georgia-based Advisory Serv Net Limited Liability has invested 0.02% in Amarin Corporation plc (NASDAQ:AMRN). Apriem reported 14,250 shares. Endurance Wealth Mngmt invested 0% in Amarin Corporation plc (NASDAQ:AMRN). Fmr Limited Liability owns 709,931 shares. Farallon Cap Limited Liability Co invested 0.39% of its portfolio in Amarin Corporation plc (NASDAQ:AMRN). Jefferies Gru Llc has 200 shares.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “FDA OKs J&J’s esketamine nasal spray for depression – Seeking Alpha” on March 05, 2019, also Seekingalpha.com with their article: “J&J dips on latest jury talc award – Seeking Alpha” published on March 14, 2019, Bizjournals.com published: “See inside Johnson & Johnson’s new $18M Lake Nona facility (PHOTOS) – Orlando Business Journal” on March 05, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson receives federal subpoenas – Seeking Alpha” published on February 21, 2019 as well as Seekingalpha.com‘s news article titled: “Novartis sues J&J over “misleading” Tremfya data – Seeking Alpha” with publication date: March 04, 2019.

Since November 7, 2018, it had 3 insider buys, and 6 sales for $74.45 million activity. Fasolo Peter sold 166,695 shares worth $24.41 million. The insider PRINCE CHARLES bought $268,731. $100,050 worth of Johnson & Johnson (NYSE:JNJ) was bought by MULCAHY ANNE M on Friday, December 14. $1.23 million worth of Johnson & Johnson (NYSE:JNJ) was sold by Kapusta Ronald A on Thursday, November 8. PEREZ WILLIAM D bought $133,910 worth of stock. 30,943 shares were sold by Sneed Michael E, worth $4.41M on Friday, November 23.

Investors sentiment decreased to 0.86 in Q4 2018. Its down 0.19, from 1.05 in 2018Q3. It turned negative, as 51 investors sold JNJ shares while 851 reduced holdings. 145 funds opened positions while 631 raised stakes. 1.79 billion shares or 5.17% more from 1.70 billion shares in 2018Q3 were reported. Qv Investors reported 1,660 shares stake. Rothschild Investment Corp Il owns 91,801 shares or 1.59% of their US portfolio. Parametric Assocs Ltd Liability reported 9.26 million shares or 1.19% of all its holdings. Interocean Capital Lc reported 233,470 shares. Lawson Kroeker Investment Management Inc Ne has 3.94% invested in Johnson & Johnson (NYSE:JNJ). Brave Asset holds 1.23% or 14,194 shares in its portfolio. Tiemann Limited has invested 2.26% in Johnson & Johnson (NYSE:JNJ). Estabrook Cap Mgmt has invested 0% in Johnson & Johnson (NYSE:JNJ). Moreover, Nelson Roberts Advisors has 0.22% invested in Johnson & Johnson (NYSE:JNJ). Payden Rygel reported 91,900 shares or 0.96% of all its holdings. Cls Invests Ltd Llc reported 0.02% of its portfolio in Johnson & Johnson (NYSE:JNJ). Fosun Int Ltd owns 7,565 shares. 23,116 were reported by Connable Office. Two Sigma Secs Lc has invested 0.02% in Johnson & Johnson (NYSE:JNJ). Liberty Cap Mngmt Inc invested in 7,023 shares or 0.56% of the stock.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart